BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhutiani N, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RC. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford). 2016;18:593-599. [PMID: 27346140 DOI: 10.1016/j.hpb.2016.03.609] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Cannon RM, Bolus DN, White JA. Irreversible Electroporation as a Bridge to Liver Transplantation. The American Surgeon 2019;85:103-10. [DOI: 10.1177/000313481908500141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Nault J, Sutter O, Nahon P, Ganne-carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. Journal of Hepatology 2018;68:783-97. [DOI: 10.1016/j.jhep.2017.10.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 100] [Article Influence: 24.8] [Reference Citation Analysis]
3 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Lorenzo MF, Thomas SC, Kani Y, Hinckley J, Lee M, Adler J, Verbridge SS, Hsu FC, Robertson JL, Davalos RV, Rossmeisl JH Jr. Temporal Characterization of Blood-Brain Barrier Disruption with High-Frequency Electroporation. Cancers (Basel) 2019;11:E1850. [PMID: 31771214 DOI: 10.3390/cancers11121850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
5 Tameez Ud Din A, Tameez-Ud-Din A, Chaudhary FMD, Chaudhary NA, Siddiqui KH. Irreversible Electroporation For Liver Tumors: A Review Of Literature. Cureus 2019;11:e4994. [PMID: 31497425 DOI: 10.7759/cureus.4994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
6 Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. J Hepatocell Carcinoma 2021;8:1181-93. [PMID: 34589446 DOI: 10.2147/JHC.S268300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hong Y, Martin RCG. Personalizing Locoregional Therapy for Patients with Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2017;13:126-35. [DOI: 10.1007/s11888-017-0356-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Crocetti L, Bargellini I, Cioni R. Loco-regional treatment of HCC: current status. Clin Radiol. 2017;72:626-635. [PMID: 28258743 DOI: 10.1016/j.crad.2017.01.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
9 Green BL, House MG. Nonsurgical Approaches to Treat Biliary Tract and Liver Tumors. Surg Oncol Clin N Am 2019;28:573-86. [PMID: 31472906 DOI: 10.1016/j.soc.2019.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sánchez-Velázquez P, Castellví Q, Villanueva A, Iglesias M, Quesada R, Pañella C, Cáceres M, Dorcaratto D, Andaluz A, Moll X, Burdío JM, Grande L, Ivorra A, Burdío F. Long-term effectiveness of irreversible electroporation in a murine model of colorectal liver metastasis. Sci Rep 2017;7:44821. [PMID: 28327623 DOI: 10.1038/srep44821] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol 2019;36:287-97. [PMID: 31680719 DOI: 10.1055/s-0039-1698755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Glassberg MB, Ghosh S, Clymer JW, Qadeer RA, Ferko NC, Sadeghirad B, Wright GW, Amaral JF. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. Onco Targets Ther 2019;12:6407-38. [PMID: 31496742 DOI: 10.2147/OTT.S204340] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 13.3] [Reference Citation Analysis]
13 Chua T, Faigel DO. Endoscopic Ultrasound-Guided Ablation of Liver Tumors. Gastrointest Endosc Clin N Am 2019;29:369-79. [PMID: 30846159 DOI: 10.1016/j.giec.2018.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Aycock KN, Davalos RV. Irreversible Electroporation: Background, Theory, and Review of Recent Developments in Clinical Oncology. Bioelectricity 2019;1:214-34. [PMID: 34471825 DOI: 10.1089/bioe.2019.0029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
15 Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017;4:49-58. [PMID: 28331845 DOI: 10.2147/jhc.s129063] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
16 Freeman E, Cheung W, Kavnoudias H, Majeed A, Kemp W, Roberts SK. Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre. Cardiovasc Intervent Radiol 2021;44:247-53. [PMID: 33051707 DOI: 10.1007/s00270-020-02666-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sugimoto K, Kakimi K, Takeuchi H, Fujieda N, Saito K, Sato E, Sakamaki K, Moriyasu F, Itoi T. Irreversible Electroporation versus Radiofrequency Ablation: Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019;30:845-853.e6. [PMID: 31126596 DOI: 10.1016/j.jvir.2019.03.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
18 Lasarte-Cia A, Lozano T, Cano D, Martín-Otal C, Navarro F, Gorraiz M, Casares N, Vivas I, Lasarte JJ. Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma. Biomed Res Int 2021;2021:8852233. [PMID: 33575350 DOI: 10.1155/2021/8852233] [Reference Citation Analysis]
19 Yu M, Li S. Irreversible electroporation for liver cancer ablation: A meta analysis. Eur J Surg Oncol 2021:S0748-7983(21)00981-1. [PMID: 35012834 DOI: 10.1016/j.ejso.2021.12.015] [Reference Citation Analysis]
20 Freeman E, Cheung W, Ferdousi S, Kavnoudias H, Majeed A, Kemp W, Roberts SK. Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison. Scand J Gastroenterol 2021;56:942-7. [PMID: 34057003 DOI: 10.1080/00365521.2021.1930145] [Reference Citation Analysis]
21 Sánchez-Velázquez P, Clavien PA. The role of the irreversible electroporation in the hepato-pancreatico-biliary surgery. Cir Esp 2017;95:307-12. [PMID: 28318494 DOI: 10.1016/j.ciresp.2017.01.007] [Reference Citation Analysis]
22 Ruarus A, Vroomen L, Puijk R, Scheffer H, Zonderhuis B, Kazemier G, van den Tol M, Berger F, Meijerink M. Irreversible Electroporation in Hepatopancreaticobiliary Tumours. Can Assoc Radiol J 2018;69:38-50. [DOI: 10.1016/j.carj.2017.10.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
23 Geboers B, Scheffer HJ, Graybill PM, Ruarus AH, Nieuwenhuizen S, Puijk RS, van den Tol PM, Davalos RV, Rubinsky B, de Gruijl TD, Miklavčič D, Meijerink MR. High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. Radiology 2020;295:254-72. [PMID: 32208094 DOI: 10.1148/radiol.2020192190] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 21.5] [Reference Citation Analysis]
24 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Martin EK, Bhutiani N, Egger ME, Philips P, Scoggins CR, McMasters KM, Kelly LR, Vitale GC, Martin RCG. Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma. HPB (Oxford) 2018;20:1092-7. [PMID: 30057125 DOI: 10.1016/j.hpb.2018.06.1806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
26 Sugimoto K, Abe M, Yoshimasu Y, Takeuchi H, Kasai Y, Itoi T. Irreversible electroporation of hepatocellular carcinoma: the role of ultrasonography. Ultrasonography 2020;39:229-37. [PMID: 32450674 DOI: 10.14366/usg.20023] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Ma YY, Shi JJ, Chen JB, Xu KC, Niu LZ. Irreversible electroporation for liver metastasis from pancreatic cancer: A case report. World J Clin Cases 2020; 8(2): 390-397 [PMID: 32047790 DOI: 10.12998/wjcc.v8.i2.390] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hong Y, Rice J, Sharma D, Martin RCG 2nd. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer. Am J Surg. 2018;216:106-110. [PMID: 29506753 DOI: 10.1016/j.amjsurg.2018.01.037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]